Results 11 to 20 of about 3,101,103 (310)

How to Classify and Define Pituitary Tumors: Recent Advances and Current Controversies

Frontiers in Endocrinology, 2021
Pituitary tumors are very complex and heterogeneous and have a very wide range of proliferative and aggressive behaviors, and how to define and classify these tumors remains controversial.
Congxin Dai, Jun Kang, Xiaohai Liu, Yong Yao, Yong Yao, Haijun Wang, Haijun Wang, Renzhi Wang, Renzhi Wang   +8 more
doaj   +2 more sources

Orthotopic pituitary tumors generated by stereotaxic GC cell injection in immunocompetent rats [PDF]

Acta Neuropathologica Communications
Innovative treatment strategies for pituitary tumors are necessary to limit the disease burden and to improve survival in cases of carcinomas. The paucity and inaccuracy of available preclinical models substantially hamper pituitary research and drug ...
Etienne Lefevre, Fanny Chasseloup, Nataly Ladurelle, Clément Janot, Jean Laurent Thibaud, Isabelle Beau, Clovis Adam, Céline des Courtils, Philippe Zizzari, Alexandre Carpentier, Peter Kamenický   +10 more
doaj   +2 more sources

Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions

Frontiers in Endocrinology, 2018
Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement
Luis V. Syro, Fabio Rotondo, Mauricio Camargo, Leon D. Ortiz, Carlos A. Serna, Kalman Kovacs   +5 more
doaj   +2 more sources

PIT-1/SF-1-positive pituitary tumors in patients with acromegaly: transcriptomic perspective [PDF]

Acta Neuropathologica Communications
Neuroendocrine pituitary tumors (PitNETs) are classified based on clinical manifestation and expression of pituitary cell lineage-specific transcription factors (TFs) and hormones.
Julia Rymuza, Qilin Zhang, Mateusz Bujko
doaj   +2 more sources

Resistance to dopamine agonists and somatostatin analogues in pituitary tumors: focus on cytoskeleton involvement

Frontiers in Endocrinology, 2015
Pituitary tumors, that origin from excessive proliferation of a specific subtype of pituitary cell, are mostly benign tumors, but may cause significant morbidity in affected patients, including visual and neurologic manifestations from mass-effect, or ...
Erika ePeverelli, Donatella eTreppiedi, Elena eGiardino, Eleonora eVitali, Andrea G Lania, Giovanna eMantovani   +5 more
doaj   +2 more sources

Pseudocapsule and pseudocapsule-based extracapsular resection in pituitary neuroendocrine tumors

Frontiers in Endocrinology, 2022
Since Costello et al. proposed the concept of pseudocapsule of pituitary neuroendocrine tumors (PitNETs) in 1936, many studies have been published on its occurrence, development process, histopathology, and morphology.
Xiao Bin Wang, Tian Yi Han, Jian Gong Ma, Cheng He, Li Xue, Xun Zhang, Zhe Bao Wu   +6 more
doaj   +1 more source

Sprouting Angiogenesis in Human Pituitary Adenomas

Frontiers in Oncology, 2022
IntroductionAngiogenesis in pituitary tumors is not fully understood, and a better understanding could help inform new pharmacologic therapies, particularly for aggressive pituitary tumors.Materials and Methods219 human pituitary tumors and 12 normal ...
Jie Zhou, Yaomin Hu, Wende Zhu, Chuansheng Nie, Wenxiu Zhao, Alexander T. Faje, Kay E. Labelle, Brooke Swearingen, Hang Lee, E. Tessa Hedley-Whyte, Xun Zhang, Pamela S. Jones, Karen K. Miller, Anne Klibanski, Yunli Zhou, Roy J. Soberman   +15 more
doaj   +1 more source

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

Pituitary, 2023
The Pituitary Society established the concept and mostly qualitative parameters for defining uniform criteria for Pituitary Tumor Centers of Excellence (PTCOEs) based on expert consensus.
A. Giustina, M. M. Uygur, S. Frara, A. Barkan, N. Biermasz, P. Chanson, P. Freda, M. Gadelha, U. Kaiser, S. Lamberts, E. Laws, L. Nachtigall, V. Popović, M. Reincke, C. Strasburger, A. J. van der Lely, J. Wass, S. Melmed, F. Casanueva   +18 more
semanticscholar   +1 more source

Costs and Its Determinants in Pituitary Tumour Surgery

Frontiers in Endocrinology, 2022
PurposeValue-based healthcare (VBHC) provides a framework to improve care by improving patient outcomes and reducing healthcare costs. To support value-based decision making in clinical practice we evaluated healthcare costs and cost drivers in ...
Alies J. Dekkers, Alies J. Dekkers, Friso de Vries, Friso de Vries, Amir H. Zamanipoor Najafabadi, Emmy M. van der Hoeven, Marco J. T. Verstegen, Marco J. T. Verstegen, Alberto M. Pereira, Alberto M. Pereira, Alberto M. Pereira, Wouter R. van Furth, Wouter R. van Furth, Nienke R. Biermasz, Nienke R. Biermasz   +14 more
doaj   +1 more source

Imaging of pituitary tumors: an update with the 5th WHO Classifications—part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma

Japanese Journal of Radiology, 2023
The pituitary gland is the body’s master gland of the endocrine glands. Although it is a small organ, many types of tumors can develop within it. The recently revised fifth edition of the World Health Organization (WHO) classifications (2021 World Health
Taro Tsukamoto, Yukio Miki
semanticscholar   +1 more source